Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancerLANGER, Corey; LILENBAUM, Rogerio.Seminars in oncology. 2004, Vol 31, Num 6, pp 8-15, issn 0093-7754, 8 p., SUP11Article

Recent advances and continuing challenges in treating patients with lung cancer and poor performance statusLILENBAUM, Rogerio; LANGER, Corey.Seminars in oncology. 2004, Vol 31, Num 6, issn 0093-7754, 33 p., SUP11Serial Issue

Quality of life considerations in patients with advanced lung cancerCELLA, David.Seminars in oncology. 2004, Vol 31, Num 6, pp 16-20, issn 0093-7754, 5 p., SUP11Article

Challenges in defining and identifying patients with non-small cell lung cancer and poor performance statusKELLY, Karen.Seminars in oncology. 2004, Vol 31, Num 6, pp 3-7, issn 0093-7754, 5 p., SUP11Article

Treatment approaches in patients with advanced non-small cell lung cancer and poor performance statusGOVINDAN, Ramaswamy; GARFIELD, David H.Seminars in oncology. 2004, Vol 31, Num 6, pp 27-31, issn 0093-7754, 5 p., SUP11Article

Drug development in patients with advanced non-small cell lung cancer and poor performance statusSTINCHCOMBE, Thomas E; SOCINSKI, Mark A.Seminars in oncology. 2004, Vol 31, Num 6, pp 21-26, issn 0093-7754, 6 p., SUP11Article

Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non―Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402LILENBAUM, Rogerio; XIAOFEI WANG; LIN GU et al.Journal of clinical oncology. 2009, Vol 27, Num 27, pp 4487-4491, issn 0732-183X, 5 p.Article

Chemotherapeutic management of stage IV non-small cell lung cancerSOCINSKI, Mark A; MORRIS, David E; MASTERS, Gregory A et al.Chest. 2003, Vol 123, Num 1, pp 226S-243S, issn 0012-3692, SUPArticle

Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancerLILENBAUM, Rogerio; SOCINSKI, Mark A; ALTORKI, Nasser K et al.Journal of clinical oncology. 2006, Vol 24, Num 30, pp 4825-4832, issn 0732-183X, 8 p.Article

Gefitinib Versus Placebo in Completely Resected Non―Small-Cell Lung Cancer: Results of the NCIC CTG BR19 StudyGOSS, Glenwood D; O'CALLAGHAN, Chris; PISTERS, Katherine et al.Journal of clinical oncology. 2013, Vol 31, Num 27, pp 3320-3326, issn 0732-183X, 7 p.Article

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung CancerSEQUIST, Lecia V; GETTINGER, Scott; SWEENEY, Jennifer et al.Journal of clinical oncology. 2010, Vol 28, Num 33, pp 4953-4960, issn 0732-183X, 8 p.Article

Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2LILENBAUM, Rogerio; AXELROD, Rita; THOMAS, Sachdev et al.Journal of clinical oncology. 2008, Vol 26, Num 6, pp 863-869, issn 0732-183X, 7 p.Article

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerSANDIER, Alan; GRAY, Robert; PERRY, Michael C et al.The New England journal of medicine. 2006, Vol 355, Num 24, pp 2542-2550, issn 0028-4793, 9 p.Article

Phase II Trial of Cetuximab in Patients With Previously Treated Non-Small-Cell Lung CancerHANNA, Nasser; LILENBAUM, Rogerio; ANSARI, Rafat et al.Journal of clinical oncology. 2006, Vol 24, Num 33, pp 5253-5258, issn 0732-183X, 6 p.Article

Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancerRITCH, Paul; RUDIN, Charles M; BITRAN, Jacob David et al.Lung cancer. 2006, Vol 52, Num 2, pp 173-180, issn 0169-5002, 8 p.Article

Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participantsLAMONT, Elizabeth B; HERNDON, James E; WEEKS, Jane C et al.Journal of the National Cancer Institute. 2005, Vol 97, Num 14, pp 1080-1083, issn 0027-8874, 4 p.Article

Differences in Clinical Trial Patient Attributes and Outcomes According to Enrollment SettingLAMONT, Elizabeth B; LANDRUM, Mary Beth; MILLER, Antonius A et al.Journal of clinical oncology. 2010, Vol 28, Num 2, pp 215-221, issn 0732-183X, 7 p.Article

Treatment of non-small cell lung cancer, Stage IV ACCP evidence-based clinical practice guidelines (2nd Edition)SOCINSKI, Mark A; CROWELL, Richard; HENSING, Thomas E et al.Chest. 2007, Vol 132, Num 3, issn 0012-3692, 277S-289S, SUPArticle

Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapyCELLA; WAGNER, Lynne; CASHY, John et al.Journal of the National Cancer Institute. Monographs. 2007, Vol 37, pp 53-60, issn 1052-6773, 8 p.Article

The evolving role of cetuximab in non-small cell lung cancerLILENBAUM, Rogerio C.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 4432s-4435s, 2Conference Paper

Extranodal lymphoplasmacytoid lymphoma (immunocytoma) presenting as small intestinal obstructionRECINE, Monica A; PEREZ, Maria T; CABELLO-INCHAUSTI, Beria et al.Archives of pathology & laboratory medicine (1976). 2001, Vol 125, Num 5, pp 677-679, issn 0363-0153Article

Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinomaLILENBAUM, Rogerio C; SCHWARTZ, Michael A; SEIGEL, Leonard et al.Cancer. 2001, Vol 92, Num 8, pp 2158-2163, issn 0008-543XArticle

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non―Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2ZUKIN, Mauro; BARRIOS, Carlos H; DA ROCHA BALDOTTO, Clarissa Serodio et al.Journal of clinical oncology. 2013, Vol 31, Num 23, pp 2849-2853, issn 0732-183X, 5 p.Conference Paper